Stocks & Investing
Tue, May 12, 2009Mon, May 11, 2009Fri, May 8, 2009Thu, May 7, 2009Wed, May 6, 2009Thu, April 16, 2009Wed, April 15, 2009Tue, April 14, 2009Mon, April 13, 2009Thu, April 9, 2009Wed, April 8, 2009Tue, April 7, 2009Mon, April 6, 2009Fri, April 3, 2009Thu, April 2, 2009Wed, April 1, 2009Tue, March 31, 2009Mon, March 30, 2009Fri, March 27, 2009Thu, March 26, 2009Wed, March 25, 2009Tue, March 24, 2009Mon, March 23, 2009Fri, March 20, 2009Thu, March 19, 2009Wed, March 18, 2009Tue, March 17, 2009Mon, March 16, 2009Fri, March 13, 2009Thu, March 12, 2009Wed, March 11, 2009Tue, March 10, 2009Mon, March 9, 2009Fri, March 6, 2009Thu, March 5, 2009Wed, March 4, 2009Tue, March 3, 2009Mon, March 2, 2009Fri, February 27, 2009Thu, February 26, 2009Wed, February 25, 2009Tue, February 24, 2009Mon, February 23, 2009Sun, February 22, 2009Fri, February 20, 2009Thu, February 19, 2009Wed, February 18, 2009Tue, February 17, 2009Mon, February 16, 2009Fri, February 13, 2009Thu, February 12, 2009Wed, February 11, 2009Tue, February 10, 2009Mon, February 9, 2009Sun, February 8, 2009Fri, February 6, 2009Thu, February 5, 2009Wed, February 4, 2009Tue, February 3, 2009Mon, February 2, 2009Fri, January 30, 2009Thu, January 29, 2009Raptor Pharmaceuticals Corp.: Global Rare Disease Day
Published in Stocks and Investing on Monday, February 23rd 2009 at 6:01 GMT, Last Modified on 2009-02-23 06:02:19 by Market Wire
NOVATO, CA--(Marketwire - February 23, 2009) -
WHAT:
Raptor Pharmaceuticals, San Francisco Bay Area biotech company, will participate in Global Rare Disease Day on February 28, 2009, joining hundreds of patient organizations, government agencies, medical societies and other drug development companies to focus attention on Rare Diseases. A Rare Disease affects fewer than 200,000 Americans, and nearly 7,000 such diseases afflict nearly 30 million Americans, according to the National Institutes of Health ("NIH").
Global Rare Disease Day website: [ www.rarediseaseday.org ]
Information on U.S. Rare Disease Day on the NORD website: [ http://www.rarediseases.org/rare_disease_day/rare_disease_day_info ]
WHEN:
February 28, 2009
RESOURCES:
Sacramento / San Francisco Bay Area families active in the fight against cystinosis, a rare genetic disorder
Researchers working towards a cure/improved treatment for cystinosis
Nephropathic cystinosis (cystinosis) is a serious lysosomal storage disease, primarily diagnosed in early childhood. If left untreated, cystinosis destroys major organ systems including the kidneys, eyes, liver, muscles, pancreas and the brain. The current treatment, cysteamine therapy, may be effective at preventing kidney failure by delaying kidney transplants in cystinosis patients. However, patient compliance is challenging due to frequent dosing and potential gastrointestinal side effects. [ http://www.raptorpharma.com/patients_cystinosis.html ]
Raptor Pharmaceuticals' DR Cysteamine product candidate is a delayed-release oral formulation of cysteamine bitartrate currently being investigated for its potential to improve the management of cystinosis by potentially reducing frequency of dosing and minimizing gastrointestinal side effects. [ http://www.raptorpharma.com/dr_cysteamine_cystinosis.html ]
About Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. ("Raptor") is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it can have the greatest potential impact. Raptor currently has product candidates in clinical development to treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("HD") which is also a rare disease, and aldehyde dehydrogenase ("ALDH2") deficiency.
Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.
For additional information, please visit [ www.raptorpharma.com ].
